Sclerosis
Reading File
Asking for Preferences
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have solid material across the major types. Let me compile the full overview.
Sclerosis: A Comprehensive Overview
"Sclerosis" (from Greek skleros, meaning "hard") refers to the pathological hardening or induration of tissue, usually from fibrosis, gliosis, or calcification. The term applies across many diseases. Below are the most clinically significant types.
1. Multiple Sclerosis (MS)
Definition & Epidemiology
MS is the most common demyelinating disease of the central nervous system. It is an autoimmune, inflammatory disease causing demyelination and axonal injury at multiple sites in the brain, optic nerves, and spinal cord. Onset typically occurs between ages 20-40, and it is approximately twice as common in women as men.
Pathogenesis
The core pathology consists of focal plaques of demyelination scattered throughout the CNS white matter (and increasingly recognized in gray matter). Classic locations include:
- Periventricular white matter
- Optic nerves
- Corpus callosum ("Dawson's fingers" on MRI)
- Cerebellar peduncles
- Dorsolateral spinal cord
Autoreactive T cells cross the blood-brain barrier and attack myelin. Inflammation is mediated by CD4+ T cells (Th1 and Th17 subtypes), CD8+ cytotoxic T cells, and B cells (which produce oligoclonal IgG bands detectable in CSF). Active plaques show perivascular lymphocytic infiltration, macrophage-mediated myelin stripping, and reactive astrogliosis - the "sclerosis" or scarring visible macroscopically.
- Goldman-Cecil Medicine, p. 2498; Neuroanatomy Through Clinical Cases, 3rd ed.
Clinical Subtypes
| Subtype | Features |
|---|---|
| Relapsing-remitting (RRMS) | Most common (~85% at onset); discrete attacks with full or partial recovery |
| Secondary progressive (SPMS) | RRMS that transitions to steady worsening |
| Primary progressive (PPMS) | Gradual worsening from onset, no distinct relapses |
Symptoms
Common symptoms across functional systems (Neuroanatomy Through Clinical Cases, Table 6.7):
- Motor: Weakness (65-100%), spasticity (73-100%), hyperreflexia, Babinski's sign
- Sensory: Vibration/position sense loss (48-82%), Lhermitte's sign (electric shock sensation down spine on neck flexion)
- Cerebellar: Ataxia (37-78%), tremor, nystagmus, dysarthria
- Visual: Optic neuritis, internuclear ophthalmoplegia
- Autonomic: Bladder dysfunction (49-93%), sexual dysfunction (33-59%)
- Psychiatric: Depression (37-54% prevalence); suicide risk 2-7x higher than the general population
Treatment
- Acute relapses: High-dose IV methylprednisolone (speeds recovery but does not alter long-term course)
- Disease-modifying therapies (DMTs): Interferons, glatiramer acetate (first-line); natalizumab, ocrelizumab, alemtuzumab (highly effective monoclonal antibodies, best when given early)
- Symptom management: Spasticity, pain, bladder/bowel/sexual dysfunction, cognitive impairment
2. Amyotrophic Lateral Sclerosis (ALS)
Definition
ALS is the most common motor neuron disease, characterized by progressive degeneration of both upper motor neurons (cortex) and lower motor neurons (brainstem and spinal cord). The name refers to the hardening (sclerosis) seen in the lateral columns of the spinal cord at autopsy.
- Mean onset: ages 54-58 years
- Sporadic ALS: 90-95% of cases
- Familial ALS (FALS): 5-10%; autosomal dominant inheritance
Key Molecular Pathology
| Gene/Protein | Association |
|---|---|
| SOD1 (superoxide dismutase 1) | First identified familial ALS mutation |
| TDP-43 (TARDBP) | Most common pathological aggregate in sporadic ALS |
| C9orf72 | Hexanucleotide repeat expansion; most common genetic cause overall |
- Robbins & Kumar Basic Pathology; Robbins, Cotran & Kumar Pathologic Basis of Disease
Clinical Features
- Combined upper motor neuron (UMN) signs: spasticity, hyperreflexia, Babinski
- Combined lower motor neuron (LMN) signs: muscle atrophy, fasciculations, hyporeflexia
- ~25% have bulbar onset: dysarthria, dysphagia (difficulty swallowing), drooling
- Dysphagia leads to aspiration risk; eventually PEG tube feeding is required
- Cognitive involvement: ~15% develop frontotemporal dementia (FTD)
- Sensory and eye movement systems are typically spared
Management
- Riluzole (glutamate antagonist) modestly extends survival
- Edaravone (free radical scavenger) for selected patients
- Multidisciplinary care: respiratory support (BiPAP/ventilation), nutrition (PEG), speech therapy, palliative care
3. Systemic Sclerosis (Scleroderma)
Definition
Systemic sclerosis (SSc) is an autoimmune disorder of connective tissue characterized by three interrelated processes: autoimmunity, obliterative vasculopathy, and progressive fibrosis in multiple organs.
- Robbins & Kumar Basic Pathology, p. 186
Classification
| Type | Features |
|---|---|
| Diffuse SSc | Widespread skin involvement, rapid progression, early visceral disease |
| Limited SSc (CREST syndrome) | Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia; skin limited to fingers/face; late visceral involvement |
Pathogenesis
- Autoimmunity: CD4+ T cells accumulate in skin; Th2 cytokines (IL-13) and TGF-β from alternatively activated macrophages drive collagen synthesis in fibroblasts. Autoantibodies: ANA, anti-Scl-70 (topoisomerase I, diffuse SSc), anti-centromere (limited SSc).
- Vascular damage: Repeated endothelial injury leads to platelet aggregation, PDGF/TGF-β release, intimal proliferation, and microvascular obliteration. Pulmonary hypertension is a serious complication.
- Fibrosis: Progressive collagen deposition in skin (dermis tightly bound to subcutis), GI tract, lungs, kidneys, heart.
Organ Involvement
- Skin: Sclerodactyly, diffuse skin thickening, loss of facial expression, Raynaud's
- GI: Esophageal dysmotility (most common GI feature), malabsorption
- Lungs: Interstitial lung disease (ILD), pulmonary arterial hypertension (major cause of death)
- Kidneys: Scleroderma renal crisis (sudden hypertension, oliguria) - treated with ACE inhibitors
- Heart: Myocardial fibrosis, arrhythmias
4. Tuberous Sclerosis (Tuberous Sclerosis Complex - TSC)
Definition
Tuberous sclerosis is a rare autosomal dominant multi-system disease caused by loss-of-function mutations in:
- TSC1 (hamartin) - chromosome 9q34
- TSC2 (tuberin) - chromosome 16p13.3
Prevalence: <1 in 5,000 births. Majority of TSC-causing mutations are in TSC2.
Mechanism
Hamartin and tuberin form a complex that inhibits mTOR signaling. Loss of this complex leads to unregulated mTOR activity, causing abnormal cellular growth and benign hamartomas across multiple organs.
Manifestations
| System | Lesion |
|---|---|
| Brain | Cortical tubers, subependymal nodules, subependymal giant cell astrocytoma (SEGA) |
| Skin | Ash-leaf hypopigmented macules (earliest sign), facial angiofibromas (adenoma sebaceum), shagreen patches, periungual fibromas |
| Kidneys | Angiomyolipomas (multiple, bilateral; bleed if >4 cm), renal cysts (~20-30%), increased risk of renal cell carcinoma |
| Heart | Rhabdomyoma (most common cardiac tumor in children) |
| Lungs | Lymphangioleiomyomatosis (LAM), especially in women |
| Eyes | Retinal hamartomas |
Clinical Consequences
- Seizures (most common presenting symptom; refractory in many)
- Intellectual disability and autism spectrum disorder
- SEGA can cause obstructive hydrocephalus
Treatment
-
mTOR inhibitors (everolimus, sirolimus) are first-line for TSC-associated renal angiomyolipomas, SEGA, and pulmonary LAM
-
Anti-epileptic therapy (vigabatrin is particularly effective for infantile spasms in TSC)
-
Harrison's Principles of Internal Medicine, 22nd ed., p. 1784-1785
5. Other Notable Scleroses
| Type | Key Features |
|---|---|
| Atherosclerosis | Hardening of arterial walls from lipid-laden plaques (atheromas); major cause of coronary artery disease, stroke, peripheral vascular disease |
| Primary lateral sclerosis (PLS) | Pure UMN variant of motor neuron disease; slower progression than ALS |
| Hepatoportal sclerosis | Obliterative portal venopathy causing non-cirrhotic portal hypertension |
| Nodular sclerosis | A subtype of Hodgkin lymphoma defined by fibrous bands dividing lymph node into nodules |
Summary Table
| Disease | Tissue Affected | Pathological Process | Key Feature |
|---|---|---|---|
| Multiple Sclerosis | CNS white matter | Demyelination + gliosis | Relapsing-remitting course; periventricular plaques |
| ALS | Motor neurons (UMN + LMN) | Neurodegeneration | Mixed UMN/LMN signs; TDP-43 aggregates |
| Systemic Sclerosis | Skin, vessels, viscera | Fibrosis + vasculopathy | Raynaud's; CREST; anti-Scl-70/anti-centromere Abs |
| Tuberous Sclerosis | Multiple organs | Hamartoma formation | mTOR dysregulation; seizures; ash-leaf macules |
| Atherosclerosis | Arteries | Lipid plaque + fibrosis | Coronary artery disease; stroke |
Sources: Robbins & Kumar Basic Pathology; Bradley and Daroff's Neurology in Clinical Practice; Neuroanatomy Through Clinical Cases, 3rd ed.; Harrison's Principles of Internal Medicine, 22nd ed.; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.